Stockreport

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF REVEAL-2, with each study exceeding its enrollment target due to strong patient demand; topline data on track for first half of 2026 - - VRDN-003 composition of matter [Read more]